[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hsil-high-grade-squamous-intraepithelial-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hsil-high-grade-squamous-intraepithelial-lesions":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100595184","screening-for-anal-cancer-in-men-who-have-sex-with-men-using-pre-exposure-prophylaxis-100595184",false,"NCT07029152","Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis","Screening for Anal Cancer in MSM Using PrEP","SCOPE","Inclusion Criteria:\n\n* HIV-uninfected MSM (men who have sex with men) aged 35 years or older.\n* participants must have been using PrEP for at least 3 months.\n* Dutch, English or French speaking and writing\n\nExclusion Criteria:\n\n* Any intervention in the (peri-)anal region within the past 3 months\n* Enema usage within 2 h before sampling\n* Currently undergoing peri-anal topical HPV-treatment\n* HRA in the last year (anal swab or HRA prior to the last year is no exclusion)","MALE","35 Years",{"count":20,"type":21},296,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, and how having HSIL affects their quality of life. We'll also test if DNA methylation testing can give us extra information about the lesions.\n\nThe main questions the study aims to answer are:\n\n* How common are HSIL in MSM using PrEP?\n* How accurate are anal swabs for detecting HSIL in this group?\n* How does having HSIL affect the quality of life of MSM using PrEP?\n* Can DNA methylation testing help improve our understanding of HSIL in these individuals?\n\nParticipants will:\n\n* Answer questions about their health and quality of life.\n* Have an anal smear collected for testing.\n* Undergo High-Resolution Anoscopy (HRA) to check for HSIL and get a biopsy if deemed necessary.",[27,28,29,30,31,32],"Anal Cancer","Squamous Intraepithelial Lesions","HSIL, High Grade Squamous Intraepithelial Lesions","LSIL, Low-Grade Squamous Intraepithelial Lesions","HPV","Squamous Cell Carcinoma",[34,35,36,37],"HIV prevention","men who have sex with men","pre-exposure prophylaxis (PrEP)","anal cancer","RECRUITING","2026-04-30",{"date":41,"type":42},"2026-05-01","ACTUAL",{"date":44,"type":42},"2025-09-23",{"date":46,"type":21},"2026-12",{"name":48,"class":49},"Universitair Ziekenhuis Brussel","OTHER",8,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100543449","phase-4-clinical-outcome-and-biomarkers-for-predicting-immunological-response-in-patients-treated-with-imiquimod-100543449","NCT06356012","Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod","Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients with High-grade Cervical Intraepithelial Lesions Treated with Imiquimod","Inclusion Criteria:\n\n* Patients between 25 and 45 years of age (reproductive age);\n* High-risk HPV carriers;\n* Residents less than 300 km from the city of Barretos-São Paulo;\n* With a histological diagnosis of high-grade cervical squamous intraepithelial lesion (CIN 3), obtained through colposcopy-guided biopsy performed at the Barretos Cancer Hospital (HCB);\n* Acceptance of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Suspicion of invasive squamous cell carcinoma or Adenocarcinoma (in situ or invasive) by colposcopy and\u002For cytology;\n* Pregnant or breastfeeding;\n* Immunodeficiency condition;\n* Previous treatment for high-grade cervical squamous intraepithelial lesion;\n* Who have been immunized for HPV;\n* Have used antibiotics in the last 30 days",true,"FEMALE","25 Years","45 Years",{"count":63,"type":21},96,[65],"PHASE4","The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.",[68,69,70],"HSIL, High-Grade Squamous Intraepithelial Lesions","Vaginal Microbiome","Biomarkers","2025-02-03",{"date":73,"type":42},"2025-02-05",{"date":75,"type":42},"2024-04-02",{"date":77,"type":21},"2028-12-31",{"name":79,"class":49},"Barretos Cancer Hospital",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":59,"minAge":4,"maxAge":61,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100460935","effect-of-hpv-integration-on-prognosis-of-young-women-with-cin2-in-china-100460935","NCT05282095","Effect of HPV Integration on Prognosis of Young Women With CIN2 in China","Effect of HPV Integration on Prognosis of Young Women With CIN2 in China: A Multi-center Cohort Study in China","Inclusion Criteria:\n\n* Female, 18 years of age or older and 45 years of age or younger, with a desire to conceive;\n* Diagnosed with HSIL (CIN2) or HSIL (CIN2-3) via cervical tissue biopsy within the past 3 months, and has not undergone cervical surgery, physical, or medication treatment;\n* The lesion area under colposcopy is less than 50% of the total cervical area within the past 3 months;\n* Plans for 12-month follow-up observation for CIN2, with no surgical, physical, or medication treatment if the disease does not progress;\n* Understands and voluntarily agrees to participate in the 12-month follow-up of this study, and signs the informed consent form.\n\nExclusion Criteria:\n\n* Cervical status at the time of enrollment as determined by colposcopy within the past three months is Type III transformation zone;\n* Pregnant or lactating;\n* History of malignant reproductive tract tumors;\n* History of hysterectomy, cervical surgery, or pelvic radiation therapy;\n* Physical therapy to the cervix within 24 months prior to enrollment;\n* The subject has a severe immune system disease that is active;\n* Long-term use of contraceptives within 12 months prior to enrollment;\n* Vaginal medication or irrigation within 72 hours prior to sampling (can re-enroll for sampling 3 days after cessation);\n* Sexual intercourse within 24 hours prior to sampling (can re-enroll for sampling 24 hours after cessation);\n* Received treatment for genital tract infections, HPV, or other STD pathogens within the past month (can re-enroll one month after cessation of treatment);\n* Used antibiotics or vaginal microecological improvement products within the past month (can re-enroll one month after cessation of use);",{"count":89,"type":21},300,"OBSERVATIONAL","Clinically, cervical precancerous lesion is one of the important diseases that endanger the life safety and fertility of young women. Women with histopathologically confirmed CIN2 need regular HPV, cervical cytology, and colposcopic biopsy if necessary to assess the outcome and progression of the disease. In this study, we intend to visit Fujian Maternal and Child Health Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science \\& Technology and other hospitals, including 300 CIN2 participants aged 45 and below diagnosed by histopathology, and collect the remaining cervical secretions and cervical exfoliated cell samples after clinical examination, even if you do not participate in this clinical study. In clinical diagnosis, treatment and follow-up, it is also necessary to collect the above specimens for relevant medical tests. Therefore, it is of great clinical and scientific significance to explore the role of HPV integrated detection in predicting the prognosis of young women with CIN2.",[93,94,95,29],"Cervical Intraepithelial Neoplasia","HPV Infection","Virus Integration","2024-09-12",{"date":98,"type":42},"2024-09-19",{"date":100,"type":42},"2022-06-01",{"date":102,"type":21},"2026-05-31",{"name":104,"class":49},"Fujian Maternity and Child Health Hospital",20]